Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

2004 • 10,779 citations

Tumor Angiogenesis: Therapeutic Implications

1971 • 9,898 citations

The biology of VEGF and its receptors

2003 • 9,272 citations

Angiogenesis in cancer and other diseases

2000 • 8,734 citations

Targeting HIF-1 for cancer therapy

2003 • 6,321 citations

Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma

1991 • 5,657 citations

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

2006 • 5,595 citations

Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

2005 • 5,086 citations

The Biology of Vascular Endothelial Growth Factor

1997 • 4,359 citations

EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

2005 • 3,807 citations

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1993 • 3,605 citations

Modes of resistance to anti-angiogenic therapy

2008 • 2,783 citations

Angiogenesis.

1992 • 2,581 citations

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

2004 • 2,481 citations

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

1996 • 2,304 citations

Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy

2001 • 2,069 citations

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

2004 • 1,935 citations

Tumor Angiogenesis

2008 • 1,854 citations

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients

2007 • 1,742 citations

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

1997 • 1,705 citations

VEGF-targeted therapy: mechanisms of anti-tumour activity

2008 • 1,604 citations

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

2005 • 1,578 citations

Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy

2002 • 1,549 citations

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

2005 • 1,510 citations

Angiogenesis in brain tumours

2007 • 1,314 citations

Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice

2001 • 1,245 citations

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

2003 • 1,236 citations

The Biology of Vascular Endothelial Growth Factor

1997 • 1,203 citations

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

2003 • 1,172 citations

Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors

2004 • 1,160 citations

Holland‐Frei Cancer Medicine

2016 • 1,097 citations

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

2008 • 832 citations

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells

2007 • 831 citations

Targeting the tumour vasculature: insights from physiological angiogenesis

2010 • 711 citations

A role for VEGF as a negative regulator of pericyte function and vessel maturation

2008 • 584 citations

PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment

2009 • 579 citations

Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma

1991 • 523 citations

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance

2009 • 478 citations

Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival

2001 • 467 citations

G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models

2009 • 462 citations

Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis

2008 • 450 citations

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents

1991 • 441 citations

Effect of p53 Status on Tumor Response to Antiangiogenic Therapy

2002 • 427 citations

Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting

2008 • 424 citations

Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer

2007 • 402 citations

Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

2009 • 323 citations

Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations

2005 • 315 citations

Pathways mediating VEGF-independent tumor angiogenesis

2009 • 310 citations

Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy

2009 • 280 citations

Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy

2008 • 252 citations

Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.

2001 • 238 citations

Antiangiogenic Therapy of Cerebral Melanoma Metastases Results in Sustained Tumor Progression via Vessel Co-Option

2004 • 226 citations

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

2009 • 224 citations

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

2008 • 221 citations

Tumor Endothelial Cells Express Epidermal Growth Factor Receptor (EGFR) but not ErbB3 and Are Responsive to EGF and to EGFR Kinase Inhibitors

2006 • 216 citations

PDGF Receptors as Targets in Tumor Treatment

2007 • 214 citations

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

2008 • 206 citations

ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

2013 • 201 citations

A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

2009 • 193 citations

Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms.

1997 • 183 citations

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts

2009 • 172 citations

Targeted Anti–Vascular Endothelial Growth Factor Receptor-2 Therapy Leads to Short-term and Long-term Impairment of Vascular Function and Increase in Tumor Hypoxia

2006 • 162 citations

Role of myeloid cells in tumor angiogenesis and growth

2008 • 159 citations

Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies

2009 • 144 citations

Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis

2010 • 139 citations

Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)

2008 • 132 citations

PDGF-C Induces Maturation of Blood Vessels in a Model of Glioblastoma and Attenuates the Response to Anti-VEGF Treatment

2009 • 112 citations

Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).

2010 • 110 citations

Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas

2004 • 96 citations

A Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of Recombinant Human Leukemia Inhibitory Factor (rhuLIF, Emfilermin, AM424) to Prevent Chemotherapy-Induced Peripheral Neuropathy

2005 • 96 citations

Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences

2003 • 89 citations

Genes and cancer

1999 • 79 citations

Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice

2010 • 71 citations

Impact of vessel maturation on antiangiogenic therapy in ovarian cancer

2008 • 62 citations

VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy

2009 • 59 citations

Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer

2009 • 56 citations

Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells

2008 • 52 citations

Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668

2005 • 43 citations

Phosphorylated Epidermal Growth Factor Receptor on Tumor-Associated Endothelial Cells Is a Primary Target for Therapy with Tyrosine Kinase Inhibitors

2008 • 43 citations

Expression of epidermal growth factor (EGF)/transforming growth factor-α by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice

2007 • 41 citations

The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels

2009 • 34 citations

Intratumoral Heterogeneity for Expression of Tyrosine Kinase Growth Factor Receptors in Human Colon Cancer Surgical Specimens and Orthotopic Tumors

2008 • 33 citations

Differential expression of hypoxia and (lymph)angiogenesis-related genes at different metastatic sites in breast cancer

2007 • 28 citations

Differential Contribution to Neuroendocrine Tumorigenesis of Parallel Egfr Signaling in Cancer Cells and Pericytes

2010 • 27 citations

Late Breaking Abstracts

2008 • 24 citations

Construction of a Novel Constitutively Active Chimeric EGFR to Identify New Targets for Therapy

2005 • 14 citations